CHICAGO, June 26,
2024 /PRNewswire/ -- The 2024 Annual Meeting of the
American Society of Clinical Oncology (ASCO), a significant event
in the global oncology community, was grandly held in Chicago, USA,
from May 31 to June 4, 2024. ASCO has
announced the list of outstanding abstracts for 2024, which
included 138 "Excellence Awards" and 5 "Special Excellence Awards."
The clinical value assessment study of Fufang E'jiao Syrup for
treating cancer-related fatigue (CRF), led by Professor
Xu Yun from Xiyuan Hospital, China
Academy of Chinese Medical Sciences, has stood out due to its
high-level evidence-based design, rigorous quality control system,
and high-standard research findings. The study has been honored
with the "Special Excellence Award" in the field of pain and
symptom management. This award aims to recognize the top-ranked
abstract in the pain and symptom management category as determined
by the Scientific Program Committee. Notably, the Fufang E'jiao
Syrup Cancer-Related Fatigue Study stands as the only clinical
research involving Chinese patent medicine among the five "Special
Excellence Awards." As the first Chinese patent medicine to secure
high-quality evidence-based medical validation for the treatment of
CRF, Fufang E'jiao Syrup offers a Chinese medicinal solution for
global CRF management and enhances the efficacy of anti-tumor
therapies.
At approximately 6 a.m.
Beijing time on June 1, Professor Xu
Yun's team, comprising Physician Gu Shanshan and Professor
Sun Lingyun, attended the ASCO Annual Meeting to receive the award.
Physician Gu Shanshan accepted the award on behalf of the team.
ASCO President Eric P. Winer, MD,
and Conquer Cancer Foundation President Howard A. Burris III, MD, extended their warm
congratulations to Professor Xu
Yun's team and commemorated the occasion with
photographs.
CRF Impacts Quality of Life and Overall
Efficacy of Anti-Tumor Treatments in Cancer Patients
Cancer-related fatigue (CRF) is a distressing, persistent, and
subjective experience characterized by physical, emotional, or
cognitive exhaustion associated with cancer or its
treatment[1]. It affects up to 70% of patients with
malignant tumors[2], with incidence rates soaring to
80%-90% among those undergoing radiotherapy and
chemotherapy[3]. CRF substantially diminishes the daily
quality of life for cancer patients, causing significant distress
and potentially leading to interruptions in anti-tumor therapies,
thereby compromising overall treatment efficacy. Addressing CRF has
become an increasingly vital focus in cancer care. Proper diagnosis
and management of CRF can enhance the quality of life for cancer
patients, extend survival rates[4], and facilitate a
more comprehensive recovery, enabling patients to better
reintegrate into family and society.
International Recognition for Fufang E'jiao
Syrup CRF Research
At the 20th Annual Meeting of the Society for Integrative
Oncology (SIO) in 2023, the abstract of the Fufang E'jiao Syrup CRF
research was honored with the "Best Abstract" award. This
recognition drew significant interest from international experts,
leading to in-depth discussions with Professor Xu Yun's team. Building on this success, further
analysis of the research results earned the "Special Excellence
Award" in the field of pain and symptom management at this year's
ASCO Annual Meeting. This achievement aligns with the ASCO theme
for the year, "The Art and Science of Cancer Care: From Comfort to
Cure." Upon receiving the award, Professor Xu Yun expressed her joy and honor in
contributing new research to enhance the quality of life for cancer
patients, offering valuable and meaningful treatment
options.
High-Quality Evidence from CRF Research
Anticipated to Inform Guideline Revisions
In 2018, the National Key R&D Program titled "Demonstration
Study on Post-Market Evidence Evaluation and Mechanism of Action of
Ten Major Chinese Patent Medicines and Classical Formulas for
Treating Major Diseases" was initiated under the leadership of
Chief Researcher Xie Yanming from the Institute of Clinical
Basic Medicine, China Academy of Chinese Medical Sciences.
Within this project, the sub-study "Clinical Value Assessment Study
of Fufang E'jiao Syrup for Treating Cancer-Related Fatigue," was
led by Professor Xu Yun from
Xiyuan Hospital, in collaboration with Dong-E-E-Jiao Co.,
Ltd. and 29 hospitals nationwide. This study represents
China's first large-scale,
multi-center evidence-based medicine study on the treatment of CRF
with Chinese patent medicine, supported by the Ministry of Science
and Technology of China.
Following extensive preliminary work, this prospective,
multi-center, randomized, double-blind, placebo-controlled trial
was conducted across 29 centers nationwide. The trial officially
commenced in April 2019, with the
first patient enrolled in October
2019, and the final follow-up completed in May 2022, spanning three years. The study
included a total of 611 CRF patients (all with moderate to severe
CRF), consisting of 210 patients with advanced non-small cell lung
cancer, 201 patients with advanced colorectal cancer, and 200
patients with advanced gastric cancer. The results demonstrated
that Fufang E'jiao Syrup significantly reduced the degree of CRF in
patients with advanced cancer and improved their quality of
life[5]. This study addresses the limitation of previous
domestic CRF research, which mainly involved single-center,
small-sample studies of low quality, and provides new insights for
global oncology experts. This study addresses the limitations of
previous domestic CRF research, which primarily involved
single-center, small-sample studies of low quality, and provides
new insights for global oncology experts. It showcases that Chinese
medicine can provide high-quality evidence through scientifically
designed, rigorously controlled large clinical trials. It is
anticipated that this study will contribute to the clinical
application of Fufang E'jiao Syrup for CRF treatment and support
future guideline updates.
Ancient Remedy, Modern Impact: Fufang E'jiao
Syrup Enhances the Global Influence of Traditional Chinese
Medicine
Fufang E'jiao Syrup traces its origins to the Ming Dynasty's
"Liangyi Paste," as detailed in Zhang Jiebin's "Jingyue Quanshu."
This contemporary Chinese medicinal compound comprises five
traditional Chinese medicine ingredients: Ejiao, Rehmannia, Red
Ginseng, Codonopsis, and Hawthorn. Ejiao is utilized to nourish the
blood, moisten dryness, and stop bleeding. Rehmannia, serving as a
primary ingredient alongside Ejiao, nourishes blood and yin while
replenishing essence and marrow. Red Ginseng and Codonopsis
significantly boost vital energy and strengthen the spleen, while
Hawthorn aids digestion, activates blood circulation, and dissolves
blood stasis. Together, these ingredients enhance the traditional
blood-nourishing effects of Ejiao and support the efficacy of Ejiao
blocks in aiding energy transportation, collectively working to
invigorate qi and nourish blood[6].
Modern pharmacological studies have demonstrated that Fufang
E'jiao Syrup can promote hematopoietic function, increase levels of
red blood cells, hemoglobin, and serum iron, improve bone marrow
suppression, and counteract the inhibitory effects of
cyclophosphamide on bone marrow hematopoiesis. Additionally, it can
elevate white blood cell counts, promote the normal division and
proliferation of hematopoietic stem cells, enhance immunity and the
phagocytic function of macrophages, and combat
fatigue[7-11]. Clinically, Fufang E'jiao Syrup is used
to treat various types of anemia, including postpartum anemia,
tumor-related anemia, and renal anemia. It also holds significant
therapeutic value in treating bone marrow suppression post-tumor
radiotherapy and chemotherapy, ovulatory dysfunction infertility in
gynecology and obstetrics, and premature ovarian failure. Following
the results of the Fufang E'jiao Syrup CRF study, the Chinese
Association of Traditional Chinese Medicine issued the "Expert
Consensus on the Clinical Application of Fufang E'jiao Syrup for
Treating Cancer-Related Fatigue with Qi and Blood Deficiency
Syndrome," providing a valuable reference for clinicians.
The attainment of international awards underscores the enhanced
global recognition of the evidence-based value of traditional
Chinese medicine, validating that Fufang E'jiao Syrup is the first
Chinese medicine to provide high-quality evidence for treating CRF.
Dong-E-E-Jiao will continue to build on the evidence-based
foundation of Fufang E'jiao Syrup, leveraging ancient formulas for
modern applications, thereby benefiting more patients
worldwide.
References
|
[1]. Chinese
Association of Traditional Chinese Medicine Group
Standard T/CACM 1522-2023 "Guideline for Integrated Chinese
and Western Medicine Diagnosis and Treatment of Cancer-Related
Fatigue."
|
[2]. Gu Shanshan, Xu
Yun, Gao Rui, et al. Exploration and Practice of Precise Clinical
Positioning of Traditional Chinese Patent Medicines After Listing:
Taking Fufang E'jiao Syrup as an Example [J]. Chinese Journal of
New Drugs, 2022, 31(15): 1462-1467.
|
[3]. Chinese
Association of Traditional Chinese Medicine. "Expert Consensus on
the Clinical Application of Fufang E'jiao Syrup for Treating
Cancer-Related Fatigue."
|
[4]. Chinese
Anti-Cancer Association Cancer Rehabilitation and Palliative Care
Professional Committee, Chinese Society of Clinical Oncology Tumor
Support and Rehabilitation Treatment Expert Committee. Chinese
Expert Consensus on the Diagnosis and Treatment of Cancer-Related
Fatigue [J]. Chinese Medical Journal, 2022, 102(3):
180-189.
|
[5]. ShanShan Gu, et
al. Efficacy of treatment with traditional Chinese patent medicine
(Fufang E'jiao Syrup) for cancer-related fatigue in patients with
advanced cancer: A randomized, double-blinded, placebo-controlled,
multicenter trial. 2024 ASCO Abstract 12053.
|
[6]. Liu Weiyan,
Ren Rujing, Gao Dengfeng, Gu Jianjun, Liu Guangyuan, Zhang Qingwei,
Zhang Yan, Liu Haibin. Research Progress on the Adjunctive
Treatment of Malignant Tumors with Fufang E'jiao Syrup [J]. Journal
of Shanghai University of Traditional Chinese Medicine, 2021,
35(01): 141-145.
|
[7]. Zhang
Mingyan, Zheng Wenke, Yang Fengwen, Li Yue, Zhang Lishuang, Zhao
Hongjie, Ji Zhaocheng, Wang Hui, Zhang Junhua. Systematic
Evaluation of the Efficacy and Safety of Fufang E'jiao Syrup in
Preventing and Treating Myelosuppression After Cancer Chemotherapy
[J]. Tianjin Journal of Traditional Chinese Medicine, 2019, 36(05):
459-465.
|
[8]. Xu Haiyu,
Wang Songsong, Yang Hongjun, Bian Baolin, Tian Shousheng, Wang
Dongliang, Lu Peng, Zhou Xiangshan, You Jinhua, Huang Luqi.
Exploring the Mechanism of Fufang E'jiao Syrup as an Adjuvant
Therapy for Tumors Based on Network Pharmacology [J]. China Journal
of Chinese Materia Medica, 2014, 39(16): 3148-3151.
|
[9]. Zhu Haifang,
Hai Juan, Zhang Lu, Zhang Yan, Chen Huihui, Zheng Hairong. Research
Progress on the Pharmacological Effects of Fufang E'jiao Syrup [J].
China Drug Evaluation, 2013, 30(03): 135-137.
|
[10]. Chen Huihui,
You Jinhua, Tian Shousheng, Zhang Yan, Feng Mingjian. Overview of
Pharmacological and Clinical Research on Fufang E'jiao Syrup [J].
China Journal of Chinese Materia Medica, 2012, 37(20):
3021-3023.
|
[11]. Liu Maoxuan.
Research on the Therapeutic Effect and Mechanism of Fufang E'jiao
Syrup on Anemia [D]. Shandong University, 2014.
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fufang-ejiao-syrups-breakthrough-research-on-cancer-related-fatigue-receives-special-excellence-award-at-2024-asco-annual-meeting-302183034.html
SOURCE Dong-E-E-Jiao Co., Ltd